These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 19433964

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
    Frankel AE, Fleming DR, Hall PD, Powell BL, Black JH, Leftwich C, Gartenhaus R.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 1):3555-61. PubMed ID: 14506141
    [Abstract] [Full Text] [Related]

  • 6. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.
    Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A.
    J Clin Oncol; 2010 Apr 10; 28(11):1870-7. PubMed ID: 20212249
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.
    Thongprasert S, Soorraritchingchai S, Chewaskulyong B, Charoentum C, Munprakan S.
    J Med Assoc Thai; 2006 Feb 10; 89(2):152-9. PubMed ID: 16579000
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
    Lin CM, Chen CH, Chang JW, Tsao TC.
    Am J Clin Oncol; 2009 Apr 10; 32(2):169-73. PubMed ID: 19307958
    [Abstract] [Full Text] [Related]

  • 10. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.
    Cancer Chemother Pharmacol; 2010 Oct 10; 66(5):889-97. PubMed ID: 20091311
    [Abstract] [Full Text] [Related]

  • 11. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A, Favaretto A, Oniga F, Festi G, Lauro S, Morabito A, Ossana L, Sartore F, DePoli F, Fiorentino MV.
    Cancer; 1996 Oct 15; 78(8):1701-7. PubMed ID: 8859183
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D, Graziano F, Isidori P, Santo A, Cetto G, Fedeli A, Rossi G, Cellerino R.
    Cancer; 1996 Jun 01; 77(11):2251-7. PubMed ID: 8635092
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
    Han JY, Lee DH, Kim HY, Hong EK, Yoon SM, Chun JH, Lee HG, Lee SY, Shin EH, Lee JS.
    Cancer; 2003 Nov 01; 98(9):1918-24. PubMed ID: 14584075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.